本帖最后由 老马 于 2012-1-13 21:20 编辑 7 _: Q( \ ^/ Z: L8 C# I* }; S
5 l' J; b+ j% p& }% g- W/ K爱必妥和阿瓦斯丁的比较, X. h) ^6 M6 e5 d) F* e3 n
7 Q- J8 w. ]# v R5 t- t
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/" A# U. O! r. F& a% j
1 J; f! N- l7 x0 y
P% ~- ?1 X# g4 c+ o
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
; X, b0 s; a; d) O: p1 q, c6 Z==================================================" i. e& A8 s( m4 v6 k0 [4 N
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)" x" M. |! s( O' K: ^
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.0 q$ L7 V! O! Q! |
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.* [6 ~ M& @; N) u
|